Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma
Conditions
Brief summary
The primary objective of this study is to assess the effect of treatment with bendamustine on cardiac repolarization as reflected by the rate-corrected QT interval by the Fridericia method (QTcF).
Detailed description
This study was originally conducted as a substudy in a subset of patients enrolled in the phase 3 study C18083/3064/NL/MN (NCT00877006) who were randomly assigned to treatment with bendamustine in combination with rituximab (BR) and who satisfied additional eligibility criteria related to cardiac function. The objective of the substudy was to obtain results to assess the effect of bendamustine treatment on cardiac polarization and any potential changes in the QT interval (corrected by the Fridericia method \[QTcF\]). After a period of time, the substudy was amended to be a separate stand-alone study to ensure that an adequate number of patients were included. Patients were treated for 6, and up to 8, cycles in the stand-alone study, and efficacy and safety were also assessed. In addition, a requirement to assess the pharmacokinetics of bendamustine and rituximab when used as combination therapy was added to the objectives, to determine the potential for drug interaction between bendamustine and rituximab.
Interventions
DRUGBendamustine
Bendamustine at 90 mg/m\^2 IV on Days 1 and 2 of a 28-day cycle.
DRUGRituximab
Rituximab at 375 mg/m\^2 IV on Day 1 of a 28-day cycle.
Sponsors
Cephalon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Histopathologic confirmation of one of the following CD20+ B-cell non-Hodgkin's lymphomas. Tissue diagnostic procedures must be performed within 6 months of study entry and with biopsy material available for review: * follicular lymphoma (grade 1 or 2) * immunoplasmacytoma/immunocytoma (Waldenstrom's macroglobulinemia) * splenic marginal zone B-cell lymphoma * extra-nodal marginal zone lymphoma of mucosa associated lymphoid tumor (MALT) type * nodal marginal zone B-cell lymphoma * mantle cell lymphoma * Meets one of the following need-for-treatment criteria (with the exception of mantle cell lymphoma for which treatment is indicated): * presence of at least one of the following B-symptoms: 1. fever (\>38ºC) of unclear etiology 2. night sweats 3. weight loss of greater than 10% within the prior 6 months * large tumor mass (bulky disease) * presence of lymphoma-related complications, including narrowing of ureters or bile ducts, tumor-related compression of a vital organ, lymphoma induced pain, cytopenias related to lymphoma/leukemia, splenomegaly, pleural effusions, or ascites * hyperviscosity syndrome due to monoclonal gammopathy * CD20-positive B cells in lymph node biopsy or other lymphoma pathology specimen * No prior treatment. Patients on watch and wait may enter the study if a recent biopsy (obtained within the last 6 months) is available. * Adequate hematologic function (unless abnormalities related to lymphoma infiltration of the bone marrow or hypersplenism due to lymphoma) as follows: * hemoglobin of \>= 10.0 g/dL * absolute neutrophil count (ANC) \>=1.5\*10\^9/L * platelet count \>=100\*10\^9/L * Bidimensionally measurable disease (field not previously radiated) * Able to provide written informed consent * Eastern Cooperative Oncology Group (ECOG) performance status \<=2 * Estimated life expectancy \>=6 months * Serum creatinine of \<=2.0 mg/dL or creatinine clearance \>=50 mL/min * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5\* upper limit of normal (ULN), and alkaline phosphatase and total bilirubin within normal limits * Left ventricular ejection fraction (LVEF) \>=50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone (R-CHOP) * A medically accepted method of contraception to be used by women of childbearing potential (not surgically sterile or at least 12 months naturally postmenopausal) * Men capable of producing offspring and not surgically sterile must practice abstinence or use a barrier method of birth control Key
Exclusion criteria
* Chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL), or grade 3 follicular lymphoma * Transformed disease. Bone marrow blasts are permitted, however, transformed disease indicating leukemic involvement is not permitted * Central nervous system (CNS) lymphomatous involvement or leptomeningeal lymphoma * Prior radiation for non-Hodgkin's lymphoma (NHL), except for a single course of locally delimited radiation therapy with a radiation field not exceeding 2 adjacent lymph node regions * Active malignancy, other than NHL, within the past 3 years except for localized prostate cancer treated with hormone therapy, cervical carcinoma in situ, breast cancer in situ, or non-melanoma skin cancer following definitive treatment * New York Heart Association (NYHA) Class III or IV heart failure, arrhythmias or unstable angina, electrocardiographic evidence of active ischemia or active conduction system abnormalities, or myocardial infarction within the last 6 months. (Prior to study entry, ECG abnormalities at screening must be documented by the investigator as not medically relevant) * Known human immunodeficiency virus (HIV) positivity * Active hepatitis B or hepatitis C infection (Hepatitis B surface antigen testing required) * Women who are pregnant or lactating * Corticosteroids for treatment of lymphoma within 28 days of study entry. Chronically administered low-dose corticosteroids (e.g., prednisone ≤20 mg/day) for indications other than lymphoma or lymphoma-related complications are permitted * Any serious uncontrolled, medical or psychological disorder that would impair the ability of the patient to receive therapy * Any condition which places the patient at unacceptable risk or confounds the ability of the investigators to interpret study data * Any other investigational agent within 28 days of study entry * Known hypersensitivity to bendamustine, mannitol, or other study-related drugs * The patient has Ann Arbor stage I disease * The patient has a history of congenital long QT syndrome * The patient has a history of cardiac disease with significant potential for QT prolongation * The patient has screening electrocardiography (ECG) on Day 1 of Cycle 1 with QTcF interval \>450 ms that is confirmed by a second ECG. If the QTcF interval is \>450 ms on both ECGs, the ECGs will be sent to eResearch Technology, Inc. (ERT), the Central ECG Reader vendor, for an overread (with 24-hour turn around time) and ERT will make a final decision on enrollment * The patient has serum potassium or magnesium less than the lower limit of normal
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change From Baseline in QT Interval as Corrected by the Fridericia Method (QTcF) at End of Infusion | Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): at the end of the 30-minute infusion. | On Day 2 of Cycle 1, three electrocardiograms (ECGs) were collected 15 minutes prior to any study drug administration. The baseline ECG interval value was obtained by averaging these 3 ECGs, and was compared to the average of the 3 ECGs taken on treatment with bendamustine at the end of the infusion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change From Baseline in QTcF at 1 Hour Postinfusion | Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): 1 hour postinfusion. | On Day 2 of Cycle 1, three ECGs were collected 15 minutes prior to any study drug administration. The baseline ECG interval value was obtained by averaging these 3 ECGs, and was compared to the average of the 3 ECGs taken on treatment with bendamustine 1 hour postinfusion. |
| Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion | Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): at the end of the 30-minute infusion and 1 hour postinfusion. | Participants were considered to have an outlier ECG value based on the most extreme value across each of the time points. New means not present at baseline and becomes present on at least 1 on-treatment ECG time point. A participant had a new outlier event (500) if the maximum QTcF was \>500 ms while their baseline was \<=500 ms, or had an outlier event (480) if the maximum QTcF was \>480 ms while their baseline was \<= 480 ms. QTcF in the 30-60 ms or \>60 ms categories were also considered outliers. |
| Number of Participants With New Onset ECG Waveform Morphological Changes | Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): at the end of the 30-minute infusion and 1 hour postinfusion. | The core ECG laboratory cardiologist assessed all leads in the ECGs and defined morphological changes. Changes from baseline (looking at each of the 3 ECGs at Day 2 Cycle 1 individually and the ECGs at all on-treatment time points individually) were noted for the following events: atrial fibrillation or flutter; second degree heart block; third degree heart block; complete right bundle branch block; complete left bundle branch block; ST segment depression; T wave abnormalities (negative T waves only); myocardial infarction pattern; any new abnormal U waves. |
| Number of Participants With Treatment-Emergent Cardiac Disorders | Adverse events were collected throughout the study and up to 30 days after the last dose of study drug. The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days. | Number of participants with cardiac disorders overall, with severity from grades 1 (mild) to grade 4 (severe), according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5= death). Participants may have reported more than 1 event. |
| Change From Baseline in QTcF at Maximum Concentration (Cmax) of Bendamustine and Its Metabolites (M3 and M4) | Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): at the end of the 30-minute infusion and 1 hour postinfusion. | Results from a pharmacokinetic-pharmacodynamic model to show the relationship of the overall predicted change from Baseline in QTcF at the average Cmax of bendamustine and its metabolites M3 and M4. |
| Model-predicted Bayesian Bendamustine Clearance in the Presence of Rituximab | Day 1 of Cycle 1: prior to start of bendamustine infusion, immediately postinfusion, 15 minutes and 30 minutes postinfusion. Day 2 of Cycle 1: 15 minutes prior to start of bendamustine infusion, 15 minutes, 30 minutes, 1, 3, and 5 hours postinfusion. | Boxplots of model-predicted Bayesian bendamustine clearance (CL) values in the presence of rituximab were generated based on the administered bendamustine doses, rate of infusion, and sample times. |
| Rituximab Concentrations at 0.5 Hours, 24 Hours, and 7 Days Postinfusion | Day 1 of Cycle 1: prior to start of rituximab infusion, immediately postinfusion. Day 2 of Cycle 1: 15 minutes prior to the start of the bendamustine infusion. Day 7 and Day 14: anytime. Day 1 of Cycle 2: prior to start of rituximab infusion. | — |
| Percentage of Participants With Complete Response (CR) | The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days. | Complete response, as defined by the International Working Group (IWG) Revised Response Criteria For Malignant Lymphoma. Results are presented for participants with non-Hodgkin lymphoma and mantle cell lymphoma as well as all participants. |
| Percentage of Participants With Overall Response | The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days. | Overall Response was comprised of those participants who had Complete Response (CR) plus those who had Partial Response (PR), as defined by the International Working Group (IWG) Revised Response Criteria For Malignant Lymphoma. Results are presented for participants with non-Hodgkin lymphoma and mantle cell lymphoma as well as all participants. |
| Overview of Adverse Events | Adverse events were collected throughout the study and up to 30 days after the last dose of study drug. The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days. | Adverse event (AE)=any untoward medical occurrence in a patient administered study drug that develops or worsens in severity during the conduct of a clinical study of a pharmaceutical product and does not necessarily have a causal relationship to the study drug. Treatment-related AEs=those that began or worsened after treatment with study drug. AE severity was graded according to the National Cancer Institute's Common Terminology Criteria for AEs (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5= death). Relationship of an AE to study drug was categorized as definite, probable, possible, unlikely, or not related. Serious AE (SAE)=one that occurred at any dose that resulted in any of the following outcomes or actions: death; a life-threatening adverse event; inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability/incapacity; a congenital anomaly/birth defect; or an otherwise important medical event. |
| Eastern Cooperative Oncology Group (ECOG) Performance Status at Endpoint | End of study. The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days. | The investigator assessed each patient's ECOG performance status according to the ECOG scale at screening, on Day 1 of each treatment cycle, and at the end-of-treatment visit. Scale scores were: 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; 2=ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5=dead. Any change in score to a higher value signifies worsening, and any change to a lower value signifies improvement. |
| Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Adverse events were collected throughout the study and up to 30 days after the last dose of study drug. The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days. | Grade 1=Mild, 2=Moderate, 3=Severe/medically significant, 4=Life-threatening. Overall is defined as the worst postbaseline grade value for each patient and laboratory test across all cycles. Only postbaseline grades are summarized. If absolute neutrophil count (ANC) and neutrophils absolute (ABS) were both measured, the worse grade value from the two was summarized. Otherwise the worst ANC grade value or the worst neutrophils ABS grade value was summarized. WBC=white blood cell; LLN=lower limit of normal |
Countries
Australia, Canada, United States
Participant flow
Pre-assignment details
Sixty-five patients were screened for this study; 8 did not meet eligibility criteria, and 3 were not enrolled for other reasons.
Participants by arm
| Arm | Count |
|---|---|
| Bendamustine With Rituximab Participants were administered bendamustine intravenous (IV) infusion at 90 mg/m\^2 on Days 1 and 2 of each 28-day cycle, and rituximab IV infusion at 375 mg/m\^2 on Day 1 of each 28-day cycle. | 54 |
| Total | 54 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
| Overall Study | Disease Progression | 1 |
| Overall Study | Early termination | 1 |
Baseline characteristics
| Characteristic | Bendamustine With Rituximab |
|---|---|
| Age, Continuous AgeContinuous | 62.9 years STANDARD_DEVIATION 10.5 |
| Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status Score=0 | 29 participants |
| Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status Score=1 | 20 participants |
| Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status Score=2 | 5 participants |
| Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status Score=3 | 0 participants |
| Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status Score=4 | 0 participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 50 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 participants |
| Race/Ethnicity, Customized Asian | 1 participants |
| Race/Ethnicity, Customized Black or African American | 0 participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 participants |
| Race/Ethnicity, Customized Other | 4 participants |
| Race/Ethnicity, Customized White | 49 participants |
| Sex: Female, Male Female | 21 Participants |
| Sex: Female, Male Male | 33 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 53 / 53 |
| serious Total, serious adverse events | 14 / 53 |
Outcome results
Primary
Mean Change From Baseline in QT Interval as Corrected by the Fridericia Method (QTcF) at End of Infusion
On Day 2 of Cycle 1, three electrocardiograms (ECGs) were collected 15 minutes prior to any study drug administration. The baseline ECG interval value was obtained by averaging these 3 ECGs, and was compared to the average of the 3 ECGs taken on treatment with bendamustine at the end of the infusion.
Time frame: Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): at the end of the 30-minute infusion.
Population: ECG Analysis Set: all enrolled participants in study who received at least 1 dose of study drug and with at least 1 available baseline and 1 on-treatment ECG; n=number of participants with measurement at given time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bendamustine With Rituximab | Mean Change From Baseline in QT Interval as Corrected by the Fridericia Method (QTcF) at End of Infusion | Baseline, n=53 | 410.4 milliseconds (ms) | Standard Deviation 23.6 |
| Bendamustine With Rituximab | Mean Change From Baseline in QT Interval as Corrected by the Fridericia Method (QTcF) at End of Infusion | End of Infusion, n=52 | 6.7 milliseconds (ms) | Standard Deviation 10.3 |
Secondary
Change From Baseline in QTcF at Maximum Concentration (Cmax) of Bendamustine and Its Metabolites (M3 and M4)
Results from a pharmacokinetic-pharmacodynamic model to show the relationship of the overall predicted change from Baseline in QTcF at the average Cmax of bendamustine and its metabolites M3 and M4.
Time frame: Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): at the end of the 30-minute infusion and 1 hour postinfusion.
Population: Pharmacokinetic-pharmacodynamic Analysis Set: all enrolled participants in study who received at least 1 dose of study drug and with at least 1 available baseline and 1 on-treatment ECG and at least 1 ECG with a time-matched plasma concentration pair.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Bendamustine With Rituximab | Change From Baseline in QTcF at Maximum Concentration (Cmax) of Bendamustine and Its Metabolites (M3 and M4) | Bendamustine | 5.4097 ms |
| Bendamustine With Rituximab | Change From Baseline in QTcF at Maximum Concentration (Cmax) of Bendamustine and Its Metabolites (M3 and M4) | Metabolite M3 | 5.9995 ms |
| Bendamustine With Rituximab | Change From Baseline in QTcF at Maximum Concentration (Cmax) of Bendamustine and Its Metabolites (M3 and M4) | Metabolite M4 | 7.1390 ms |
Secondary
Eastern Cooperative Oncology Group (ECOG) Performance Status at Endpoint
The investigator assessed each patient's ECOG performance status according to the ECOG scale at screening, on Day 1 of each treatment cycle, and at the end-of-treatment visit. Scale scores were: 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; 2=ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5=dead. Any change in score to a higher value signifies worsening, and any change to a lower value signifies improvement.
Time frame: End of study. The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days.
Population: Safety Analysis Set: enrolled participants who received 1 or more doses of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bendamustine With Rituximab | Eastern Cooperative Oncology Group (ECOG) Performance Status at Endpoint | Improved | 10 participants |
| Bendamustine With Rituximab | Eastern Cooperative Oncology Group (ECOG) Performance Status at Endpoint | Stayed the same | 35 participants |
| Bendamustine With Rituximab | Eastern Cooperative Oncology Group (ECOG) Performance Status at Endpoint | Worsened | 8 participants |
Secondary
Mean Change From Baseline in QTcF at 1 Hour Postinfusion
On Day 2 of Cycle 1, three ECGs were collected 15 minutes prior to any study drug administration. The baseline ECG interval value was obtained by averaging these 3 ECGs, and was compared to the average of the 3 ECGs taken on treatment with bendamustine 1 hour postinfusion.
Time frame: Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): 1 hour postinfusion.
Population: ECG Analysis Set: all enrolled participants in study who received at least 1 dose of study drug and with at least 1 available baseline and 1 on-treatment ECG.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bendamustine With Rituximab | Mean Change From Baseline in QTcF at 1 Hour Postinfusion | Baseline | 410.4 ms | Standard Deviation 23.6 |
| Bendamustine With Rituximab | Mean Change From Baseline in QTcF at 1 Hour Postinfusion | 1 Hour Postinfusion | 4.1 ms | Standard Deviation 9.8 |
Secondary
Model-predicted Bayesian Bendamustine Clearance in the Presence of Rituximab
Boxplots of model-predicted Bayesian bendamustine clearance (CL) values in the presence of rituximab were generated based on the administered bendamustine doses, rate of infusion, and sample times.
Time frame: Day 1 of Cycle 1: prior to start of bendamustine infusion, immediately postinfusion, 15 minutes and 30 minutes postinfusion. Day 2 of Cycle 1: 15 minutes prior to start of bendamustine infusion, 15 minutes, 30 minutes, 1, 3, and 5 hours postinfusion.
Population: Pharmacokinetic Analysis Set: all enrolled participants in study who received at least 1 dose of study drug and with at least 1 quantifiable bendamustine plasma concentration.
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| Bendamustine With Rituximab | Model-predicted Bayesian Bendamustine Clearance in the Presence of Rituximab | 32.9 L/h | Full Range 12.8 |
Secondary
Number of Participants With New Onset ECG Waveform Morphological Changes
The core ECG laboratory cardiologist assessed all leads in the ECGs and defined morphological changes. Changes from baseline (looking at each of the 3 ECGs at Day 2 Cycle 1 individually and the ECGs at all on-treatment time points individually) were noted for the following events: atrial fibrillation or flutter; second degree heart block; third degree heart block; complete right bundle branch block; complete left bundle branch block; ST segment depression; T wave abnormalities (negative T waves only); myocardial infarction pattern; any new abnormal U waves.
Time frame: Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): at the end of the 30-minute infusion and 1 hour postinfusion.
Population: ECG Analysis Set: all enrolled participants in study who received at least 1 dose of study drug and with at least 1 available baseline and 1 on-treatment ECG.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Bendamustine With Rituximab | Number of Participants With New Onset ECG Waveform Morphological Changes | 0 participants |
Secondary
Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion
Participants were considered to have an outlier ECG value based on the most extreme value across each of the time points. New means not present at baseline and becomes present on at least 1 on-treatment ECG time point. A participant had a new outlier event (500) if the maximum QTcF was \>500 ms while their baseline was \<=500 ms, or had an outlier event (480) if the maximum QTcF was \>480 ms while their baseline was \<= 480 ms. QTcF in the 30-60 ms or \>60 ms categories were also considered outliers.
Time frame: Baseline ECGs (Day 2 of Cycle 1): 15 minutes prior to bendamustine infusion. Postinfusion ECGs (Day 2 of Cycle 1): at the end of the 30-minute infusion and 1 hour postinfusion.
Population: ECG Analysis Set: all enrolled participants in study who received at least 1 dose of study drug and with at least 1 available baseline and 1 on-treatment ECG; n=number of participants with measurement at given time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bendamustine With Rituximab | Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion | QTcF New >500 ms at End of Infusion; n=52 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion | QTcF New >500 ms 1 Hour Postinfusion; n=53 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion | QTcF New >480 ms at End of Infusion; n=52 | 1 participants |
| Bendamustine With Rituximab | Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion | QTcF New >480 ms 1 Hour Postinfusion; n=53 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion | QTcF New >60 ms at End of Infusion; n=52 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion | QTcF New >60 ms 1 Hour Postinfusion; n=53 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion | QTcF New 30-60 ms at End of Infusion; n=52 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion | QTcF New 30-60 ms 1 Hour Postinfusion; n=53 | 0 participants |
Secondary
Number of Participants With Treatment-Emergent Cardiac Disorders
Number of participants with cardiac disorders overall, with severity from grades 1 (mild) to grade 4 (severe), according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5= death). Participants may have reported more than 1 event.
Time frame: Adverse events were collected throughout the study and up to 30 days after the last dose of study drug. The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days.
Population: Safety Analysis Set: enrolled participants who received 1 or more doses of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | ECG QT prolonged: Overall | 3 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | ECG QT prolonged: Grade >/=3 | 2 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Blood pressure decreased: Overall | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Blood pressure decreased: Grade >/=3 | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Cardiac murmur: Overall | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Cardiac murmur: Grade >/=3 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | ECG ST segment abnormal: Overall | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | ECG ST segment abnormal: Grade >/=3 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Heart rate irregular: Overall | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Heart rate irregular: Grade >/=3 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Palpitations: Overall | 2 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Palpitations: Grade >/=3 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Arteriosclerosis coronary artery: Overall | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Arteriosclerosis coronary artery: Grade >/=3 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Atrial fibrillation: Overall | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Atrial fibrillation: Grade >/=3 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Cardiac failure congestive: Overall | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Cardiac failure congestive: Grade >/=3 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Left ventricular dysfunction: Overall | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Left ventricular dysfunction: Grade >/=3 | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Sinus tachycardia: Overall | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Sinus tachycardia: Grade >/=3 | 0 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Tachycardia: Overall | 1 participants |
| Bendamustine With Rituximab | Number of Participants With Treatment-Emergent Cardiac Disorders | Tachycardia: Grade >/=3 | 0 participants |
Secondary
Overview of Adverse Events
Adverse event (AE)=any untoward medical occurrence in a patient administered study drug that develops or worsens in severity during the conduct of a clinical study of a pharmaceutical product and does not necessarily have a causal relationship to the study drug. Treatment-related AEs=those that began or worsened after treatment with study drug. AE severity was graded according to the National Cancer Institute's Common Terminology Criteria for AEs (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5= death). Relationship of an AE to study drug was categorized as definite, probable, possible, unlikely, or not related. Serious AE (SAE)=one that occurred at any dose that resulted in any of the following outcomes or actions: death; a life-threatening adverse event; inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability/incapacity; a congenital anomaly/birth defect; or an otherwise important medical event.
Time frame: Adverse events were collected throughout the study and up to 30 days after the last dose of study drug. The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days.
Population: Safety Analysis Set: enrolled participants who received 1 or more doses of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bendamustine With Rituximab | Overview of Adverse Events | Any adverse event | 53 participants |
| Bendamustine With Rituximab | Overview of Adverse Events | Severe adverse events (grade 3, 4, 5) | 33 participants |
| Bendamustine With Rituximab | Overview of Adverse Events | Treatment-related adverse events | 52 participants |
| Bendamustine With Rituximab | Overview of Adverse Events | Deaths | 1 participants |
| Bendamustine With Rituximab | Overview of Adverse Events | Other serious adverse events | 14 participants |
| Bendamustine With Rituximab | Overview of Adverse Events | Withdrawn from study due to adverse events | 1 participants |
Secondary
Percentage of Participants With Complete Response (CR)
Complete response, as defined by the International Working Group (IWG) Revised Response Criteria For Malignant Lymphoma. Results are presented for participants with non-Hodgkin lymphoma and mantle cell lymphoma as well as all participants.
Time frame: The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days.
Population: Full Analysis Set: all enrolled participants who received at least 1 dose of both bendamustine and rituximab and who had both a baseline and at least 1 postbaseline tumor response evaluation.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Bendamustine With Rituximab | Percentage of Participants With Complete Response (CR) | 40 percentage of participants |
| Mantle Cell Lymphoma | Percentage of Participants With Complete Response (CR) | 55 percentage of participants |
| Total | Percentage of Participants With Complete Response (CR) | 43 percentage of participants |
Secondary
Percentage of Participants With Overall Response
Overall Response was comprised of those participants who had Complete Response (CR) plus those who had Partial Response (PR), as defined by the International Working Group (IWG) Revised Response Criteria For Malignant Lymphoma. Results are presented for participants with non-Hodgkin lymphoma and mantle cell lymphoma as well as all participants.
Time frame: The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days.
Population: Full Analysis Set: all enrolled participants who received at least 1 dose of both bendamustine and rituximab and who had both a baseline and at least 1 postbaseline tumor response evaluation.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Bendamustine With Rituximab | Percentage of Participants With Overall Response | 93 percentage of participants |
| Mantle Cell Lymphoma | Percentage of Participants With Overall Response | 100 percentage of participants |
| Total | Percentage of Participants With Overall Response | 94 percentage of participants |
Secondary
Rituximab Concentrations at 0.5 Hours, 24 Hours, and 7 Days Postinfusion
Time frame: Day 1 of Cycle 1: prior to start of rituximab infusion, immediately postinfusion. Day 2 of Cycle 1: 15 minutes prior to the start of the bendamustine infusion. Day 7 and Day 14: anytime. Day 1 of Cycle 2: prior to start of rituximab infusion.
Population: Pharmacokinetic Analysis Set: all enrolled participants in study who received at least 1 dose of study drug and with at least 1 quantifiable serum concentration of rituximab.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Bendamustine With Rituximab | Rituximab Concentrations at 0.5 Hours, 24 Hours, and 7 Days Postinfusion | 7 Days Postinfusion; n=17 | 30.5 mcg/mL |
| Bendamustine With Rituximab | Rituximab Concentrations at 0.5 Hours, 24 Hours, and 7 Days Postinfusion | 0.5 Hours Postinfusion; n=19 | 173.0 mcg/mL |
| Bendamustine With Rituximab | Rituximab Concentrations at 0.5 Hours, 24 Hours, and 7 Days Postinfusion | 24 Hours Postinfusion; n=19 | 105.0 mcg/mL |
Secondary
Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall
Grade 1=Mild, 2=Moderate, 3=Severe/medically significant, 4=Life-threatening. Overall is defined as the worst postbaseline grade value for each patient and laboratory test across all cycles. Only postbaseline grades are summarized. If absolute neutrophil count (ANC) and neutrophils absolute (ABS) were both measured, the worse grade value from the two was summarized. Otherwise the worst ANC grade value or the worst neutrophils ABS grade value was summarized. WBC=white blood cell; LLN=lower limit of normal
Time frame: Adverse events were collected throughout the study and up to 30 days after the last dose of study drug. The median number of 28-day cycles was 6.0. The median duration of the treatment period was 143 days.
Population: Safety Analysis Set: enrolled participants who received 1 or more doses of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | ANC, Grade 1: <LLN - 1.5*10^9/L | 5 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | ANC, Grade 2: <1.5 - 1.0*10^9/L | 12 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | ANC, Grade 3: <1.0 - 0.5*10^9/L | 11 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | ANC, Grade 4: <0.5*10^9/L | 12 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | ANC, Grade 1-4 | 40 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Hemoglobin, Grade 1: <LLN - 100 g/L | 36 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Hemoglobin, Grade 2: <100 - 80 g/L | 12 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Hemoglobin, Grade 3: <80 - 65 g/L | 1 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Hemoglobin, Grade 4: <65 g/L | 0 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Hemoglobin, Grade 1-4 | 49 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Lymphocytes ABS, Grade 1: <LLN - 0.8*10^9/L | 0 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Lymphocytes ABS, Grade 2: <0.8 - 0.5*10^9/L | 2 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Lymphocytes ABS, Grade 3: <0.5 - 0.2*10^9/L | 13 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Lymphocytes ABS, Grade 4: <0.2*10^9/L | 22 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Lymphocytes ABS, Grade 1-4 | 37 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Platelets, Grade 1: <LLN - 75.0*10^9/L | 19 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Platelets, Grade 2: <75.0 - 50.0*10^9/L | 9 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Platelets, Grade 3: <50.0 - 25.0*10^9/L | 3 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Platelets, Grade 4: <25.0*10^9 /L | 1 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | Platelets, Grade 1-4 | 32 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | WBC, Grade 1: <LLN - 3.0*10^9/L | 9 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | WBC, Grade 2: <3.0 - 2.0*10^9/L | 19 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | WBC, Grade 3: <2.0 - 1.0*10^9/L | 15 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | WBC, Grade 4: <1.0*10^9/L | 5 participants |
| Bendamustine With Rituximab | Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall | WBC, Grade 1-4 | 48 participants |